With new technologies that allow drugs to be tested directly in human biological systems, researchers are beginning to ...

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio ...

According to GSK, the programme of 'Grand Challenge' research projects will make use of AI and other cutting-edge ...

Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result ...

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...

Towards that end, the European Society for Medical Oncology (ESMO) has developed a new guidance document that outlines the ...

The launch of Sandoz's Tyruko biosimilar of Tysabri (natalizumab) comes two years after the product was approved by the FDA, ...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical ...

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy US biotech Halda Therapeutics and ...

The announcement takes the total raised by Sofinnova Partners in the last year to €1.5 billion, and comes shortly after Anglo ...

Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical backbone that has emerged over the company’s long ...

BMS and J&J's Librexia AF study is also comparing milvexian to Eliquis to see if it can prevent stroke and other clotting ...